Findings from two early clinical studies suggest a new dual-action antimalarial drug candidate is well tolerated in humans. The first-in-class clinical candidate, MK7602, is being developed by WEHI ...
Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA ...
Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient P ...
Kalohexis, a newly created biotechnology company to advance the clinical development of a portfolio of drug candidates harnessing the melanocortin (MC) system for the treatment of metabolic disorders ...
Chief Executive Officer — Dr. Sergio Traversa Chief Medical Officer, Oncology — Dr. Raj S. Pruthi Chief Financial Officer — Maged S. Shenouda With me on today's call are Relmada Therapeutics, Inc.'s ...
Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing ...
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
Baystreet.ca News Commentary — The global precision oncology market is on pace to reach $303 billion in 2035[1], a figure that reflects more than steady growth, signaling a structural ...
After a meeting with the FDA, the company believes the agency is aligned with its development plan to start a Phase III registrational trial in CLDN 18.2-, PD-L1-positive tumors.
A viral claim that ChatGPT has cured a dog's cancer has been debunked — human scientists performed the work, and the treatment remains unproven.
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...
Hosted on MSN
Should medical marijuana be less stringently regulated? A drug policy expert explains what’s at stake
(The Conversation) – Medical marijuana could soon be reclassified into a medical category that includes prescription drugs like Tylenol with codeine, ketamine and anabolic steroids. That’s because in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results